Liquidia (LQDA) Capital Expenditures Growth (1y) (2021 - 2026)
Powered by 
Analysis
Liquidia (LQDA) Capital Expenditures Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.43 Bn | 625.67 Bn | 17.26 Bn | 26.65% |
| 2 | AbbVie | 442.46 Bn | 435.89 Bn | 12.70 Bn | 19.70% |
| 3 | Merck | 366.77 Bn | 359.63 Bn | 12.21 Bn | 16.88% |
| 4 | Novartis Ag | 266.59 Bn | 258.90 Bn | 11.24 Bn | 3.02% |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | -13.75% |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | -34.92% |
| 9 | United Therapeutics | 21.53 Bn | 18.87 Bn | 683.80 Mn | 73.63% |
| 10 | Liquidia | 6.11 Bn | 5.82 Bn | 160.92 Mn | 8.74% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8.74% |
| Mar 31, 2026 | 42.43% |
| Dec 31, 2025 | -35.51% |
| Sep 30, 2025 | -265.63% |
| Jun 30, 2025 | 509.75% |
| Mar 31, 2025 | 488.30% |
| Dec 31, 2024 | 1,433.98% |
| Sep 30, 2024 | 1,069.89% |
| Jun 30, 2024 | 364.20% |
| Mar 31, 2024 | 114.75% |
| Dec 31, 2023 | -58.04% |
| Sep 30, 2023 | 405.32% |
| Jun 30, 2023 | 2,109.09% |
| Mar 31, 2023 | 9,250.00% |
| Dec 31, 2022 | 2,355.00% |
| Jun 30, 2022 | -68.57% |
| Mar 31, 2022 | -107.69% |
| Dec 31, 2021 | -48.67% |
| Jun 30, 2021 | -91.43% |
| Mar 31, 2021 | -71.46% |